Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/30/2025

Iron Supplementation in Hemodialysis Patients

Evidence and Guidelines

  • The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend maintaining transferrin saturation ≥20% and serum ferritin ≥100 ng/mL in hemodialysis patients receiving erythropoiesis-stimulating agents, as most hemodialysis patients require intravenous iron supplementation due to substantial blood losses from dialysis procedures, blood sampling, and gastrointestinal bleeding that cannot be compensated by oral absorption 1
  • The American Journal of Kidney Diseases recommends initial dosing of 100-125 mg IV at each hemodialysis session for 8-10 consecutive doses for iron-deficient hemodialysis patients (TSAT <20% and/or ferritin <100 ng/mL) 1
  • Maintenance doses typically range from 25-125 mg/week to maintain hemoglobin targets while preventing iron overload, with monitoring of iron status (TSAT and ferritin) at least every 3 months during maintenance therapy 1

Critical Safety Considerations

  • Liver transplant patients warrant heightened vigilance for iron overload, as the liver is the main storage site for iron, and hepatic iron concentration correlates closely with total body iron stores 2, 3
  • Withhold IV iron when TSAT >50% and/or serum ferritin >800 ng/mL for up to 3 months, then reassess before resuming at reduced doses 1
  • Post-mortem studies showed that even massive hepatic siderosis was not associated with significant hepatocellular damage in the absence of viral hepatitis, though focal portal fibrosis can occur 4
  • Liver enzymes are seldom elevated with hepatic siderosis alone, so ferritin and TSAT remain the primary monitoring parameters 4

Important Considerations

  • Do not assume oral iron is adequate—hemodialysis patients almost universally require IV iron supplementation to maintain adequate stores during ESA therapy 1
  • Do not rely solely on ferritin levels in the setting of acute inflammation or infection, as ferritin is an acute-phase reactant and may be falsely elevated 5

Administration of Iron Therapy in Hemodialysis Patients

Iron Administration Safety

  • Iron therapy is essential for hemoglobin formation in hemodialysis patients, who experience high iron losses and often require intravenous supplementation, according to the American Journal of Kidney Diseases 6
  • The maximum weekly dose of iron sucrose is 500 mg, with a maximum single dose of 200 mg, as recommended by clinical guidelines 7
  • Target parameters for iron therapy in hemodialysis patients include maintaining transferrin saturation ≥20% and serum ferritin ≥100 ng/mL, as suggested by the American Journal of Kidney Diseases 6
  • Iron overload risk increases when serum ferritin levels chronically remain above 500-1000 ng/mL, as reported by the American Journal of Kidney Diseases 8

Monitoring and Dosing Considerations

  • Before administering additional iron, serum ferritin and transferrin saturation should be assessed to prevent iron overload, as recommended by the American Journal of Kidney Diseases 6
  • If iron administration is deemed necessary after appropriate assessment, the single dose should be limited to 200mg maximum and the total weekly dose should not exceed 500mg, according to clinical guidelines 7
  • Monitor for potential adverse effects including hypotension, flushing, and abdominal cramps, as advised by clinical guidelines 7